Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 132.02B |
| Revenue (ttm) | 49.19B |
| Net Income (ttm) | 9.28B |
| Beta | 0.23 |
| EPS (ttm) | 4.6 |
| PE Ratio (ttm) | 14.05 |
| Forward PE | 9.86 |
| P/B (ttm) | 5.92 |
| P/S (ttm) | 2.68 |
| Earnings Date | Oct 29, 2026 |
| Ask | n/a |
| Volume | 7,288,037 |
| Avg. Volume (20D) | 12,404,732 |
| Open | 63.60 |
| Previous Close | 63.83 |
| Day's Range | 63.36 - 64.73 |
| 52-Week Range | 42.52 - 68.10 |
| Analyst | Buy |
| Price Target | 68 (5.21%) |
| Dividends | $2.52 (3.9%) |
| Ex-Dividend Date | Jul 2, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy f...
Financial Performance
In 2025, Bristol-Myers Squibb's revenue was 48.2B, a decrease of -0.22% compared to the previous year's 48.3B. Earnings were 7.05B, a decrease of -178.83%.
Financial StatementsAnalyst Forecast
According to 24 analyst ratings, the average rating for BMY stock is "Buy". The 12-month stock price forecast is 68, which is upside of 5.21% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
